Thrombosis And Cardiovascular Diseases (advances In Experimental Medicine And Biology, 164)

Four years ago when the first European Symposium on the re­ lationship between alterations of blood clotting mechanisms and atherosclerosis was organized, we asked ourselves which would be the best way to obtain both scientific and practical contributions. We have been interested in cardiovascular diseases for several years now and have therefore focused our attention on the "container" (Le. the blood vessel) rather than on the "contents" (Le. the various components of blood) as considered only from a haemodynamic point of view. In recent years correlations were found between alterations of vascular wall and alteration of coagulative, fibrinolytic, and plate­ let factors as well as of haemorheological phenomena in the thrombo­ genic evolution of atherosclerotic lesions. A close cooperation between cardiologists and workers interested in atherosclerosis and thrombosis is therefore necessary. We think that the most appropriate approach to the various problems concerning correlations between thrombogenic and atherosclerotic lesions is co-operation between experts in these different fields of research. We thus decided to organize the 2nd Symposium taking into account the great progress achieved in this field during the past few years, and hope that discussions on diagnostic and therapeutical perspec'­ tives will yield useful elements both for the cardiologist and for the cardiologist and for the general practitioner. Front Matter....Pages i-xi Front Matter....Pages 1-1 Haemostatic Function and Ischaemic Heart Disease....Pages 3-9 Pathophysiology of Arterial Thrombosis....Pages 11-18 Clotting System in Prethrombotic State....Pages 19-29 Platelet Function Tests and Coronary Heart Disease....Pages 31-47 Impairment of Fibrinolysis and Vascular Disease....Pages 49-56 Front Matter....Pages 57-57 Antithrombin III and Atherosclerosis....Pages 59-63 Factor VIII and Antithrombin III in Atherosclerosis Obliterans of the Lower Limbs....Pages 65-80 Advances in the Prevention of Venous Thromboembolic Disease....Pages 81-83 Current Status of Anticoagulant Treatment....Pages 85-96 Front Matter....Pages 97-97 Blood Viscosity and the Complications of Diabetes....Pages 99-103 Factors Contributing to Platelet Hyperactivity in Diabetes Mellitus....Pages 105-110 Platelet Activity and Blood Lipid Changes in Diabetes Mellitus....Pages 111-117 Platelet Prostaglandins and Related Compounds in Diabetes Mellitus....Pages 119-125 Front Matter....Pages 127-127 Risk Factors for Coronary Heart Disease and Platelet Functions....Pages 129-144 On the Mechanism of Platelet Activation During Hemostasis and Thrombosis and on the Effects of Platelet Inhibiting Drugs....Pages 145-154 Methods for the Detection of Activated Platelets....Pages 155-166 Platelet Function Changes in Acute Myocardial Infarction....Pages 167-173 Role of Prostacyclin and Thromboxane A 2 in Ischaemic Heart Disease....Pages 175-185 Gyki 14,451, a Synthetic Tripeptide Inhibitor of Thrombin: “In Vitro” and “In Vivo” Studies....Pages 187-192 Prostacyclin and its Analogues for the Therapy of Thromboembolic Disorders....Pages 193-209 Front Matter....Pages 127-127 Prostacyclin in the Treatment of Atherosclerosis Obliterans and Other Vascular Diseases....Pages 211-214 Front Matter....Pages 215-215 Molecular Mechanism of Fibrinolysis....Pages 217-228 The Biological Role of Fibrinolysis....Pages 229-234 Fibrinolysis and Body Weight: Fibrinolytic Response to Venous Occlusion in Obese Children....Pages 235-242 Fibrinolytic Vessel Wall Activator in Arterial Thrombosis....Pages 243-249 Long-Term Induction of Fibrinolytic Activity in Chronic Arterial Vessel Disease....Pages 251-254 Front Matter....Pages 255-255 Free (Unconjugated) Catecholamine Concentrations in Platelets: Biological Significance and Clinical Implications....Pages 257-268 Prostaglandins and Hypertension....Pages 269-281 Effects of Antihypertensive Treatment on Peripheral Flow of the Lower Limbs....Pages 283-297 Haemodynamic and Antihypertensive Effect of Prostacyclin....Pages 299-305 Front Matter....Pages 307-307 Mechanisms Underlying Pulmonary Hypertension by Hypoxemia....Pages 309-323 Platelets, Hypoxemia and Pulmonary Hypertension....Pages 325-333 The Diagnosis and Management of Pulmonary Embolism....Pages 335-337 Platelet Activity in Relation to Smoke and Exercise in Patients with Chronic Obstructive Lung Disease: Effects of Platelet Antiaggregating Drugs....Pages 339-357 Vasodilator Treatment of Primary Pulmonary Hypertension....Pages 359-368 The Thrombogenic Risk in Chronic Respiratory Failure....Pages 369-375 Round Table on “Pulmonary Vascular Diseases”: Final Remarks....Pages 377-378 Front Matter....Pages 379-379 Basic Rheology of Mammalian Blood: Factors Promoting and Factors Interfering with Fluidity of Blood....Pages 381-392 The Red Cell as a Risk Factor in Circulatory Diseases....Pages 393-397 Hemorheological Parameters in Some Vascular Diseases....Pages 399-409 Front Matter....Pages 379-379 Evaluation of the Haemorheological Determinants in Coronary Heart Disease....Pages 411-416 Back Matter....Pages 417-426